

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Levine, et al.	Docket No.:	39766-0157R1C1
Serial No.:	10/628,770	Group Art Unit:	1643
Filing Date:	July 28, 2003	Examiner:	Holleran, Anne L.
For:	POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME		

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.


Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith;  
and
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39766-1571C1).

Respectfully submitted,

Dated: April 4, 2007

By:   
Ginger R. Dreger, Esq.  
Reg. No. 33,055

**HELLER EHRMAN LLP**  
Customer No. 25213  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>			<b>ATTY. DOCKET NO.:</b> 39766-0157R1C1		<b>SERIAL NO.:</b> 10/628,770		
			<b>APPLICANT :</b> LEVINE, et al.				
			<b>FILING DATE:</b> 7/28/03		<b>GROUP:</b> 1643		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
Bost, et al., "The JUN Kinase/Stress-activated Protein Kinase Pathway is Required for Epidermal Growth Factor Stimulation of Growth of Human A549 Lung Carcinoma Cells", The Journal of Biological Chemistry, 272(52); 33422-33429 (1997).							
Carter, et al., "Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis", Clinical Cancer Research 10:3448-3456 (2004).							
Kumar, et al., "p21-activated Kinases in Cancer", Nature Reviews/Cancer, 6:459471 (2006).							
O'Hagan, et al., "The PEA3 Ets Transcription Factor is a Downstream Target of the HER2/Neu Receptor Tyrosine Kinase", Oncogene 16:301-310 (1998).							
Potapova, et al., "Targets of c-Jun NH <sub>2</sub> -terminal Kinase 2-mediated Tumor Growth Regulation Revealed by Serial Analysis of Gene Expression", Cancer Research 62:3257-3263 (2002).							
Tancypill, et al., "Identification of Wnt Responsive Genes Using a Murine Mannary Epithelial Cell Line Model System", BMC Developmental Biology, 4:6 (2004).							
Tao, et al., <i>Wrch-1</i> , a Novel Member of the Rho Gene Family that is Regulated by Wnt-1", Genes & Development 15:1796-1807 (2001).							
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.